Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Alessandro Rizzo, Riccardo Carloni, Angela Dalia Ricci, Antonio Cusmai, Mariarita Laforgia, Concetta Calabrò, Valentina Ungaro, Donato Oreste, Mario Sollitto, Gennaro Palmiotti & Giovanni Brandi. (2023) Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis. Expert Opinion on Drug Safety 22:4, pages 323-329.
Read now
Read now
Alessandro Rizzo & Angela Dalia Ricci. (2022) PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?. Expert Opinion on Investigational Drugs 31:4, pages 415-423.
Read now
Read now
Alessandro Rizzo, Vincenzo Dadduzio, Angela Dalia Ricci, Francesco Massari, Alessandro Di Federico, Gennaro Gadaleta-Caldarola & Giovanni Brandi. (2022) Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?. Expert Opinion on Investigational Drugs 31:4, pages 371-378.
Read now
Read now
Alessandro Rizzo, Angela Dalia Ricci, Gennaro Gadaleta-Caldarola & Giovanni Brandi. (2021) First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Review of Gastroenterology & Hepatology 15:11, pages 1245-1251.
Read now
Read now
Hui Li. (2021) Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Review of Gastroenterology & Hepatology 15:3, pages 217-233.
Read now
Read now
Yike Huang, Lu Hu, Shan Huang, Wanjun Xu, Jingyuan Wan, Dandan Wang, Guocan Zheng & Zhining Xia. (2018) Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration. International Journal of Nanomedicine 13, pages 8309-8323.
Read now
Read now
Oliver Waidmann. (2018) Recent developments with immunotherapy for hepatocellular carcinoma. Expert Opinion on Biological Therapy 18:8, pages 905-910.
Read now
Read now
Articles from other publishers (25)
Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, Giorgio Frega, Andrea Palloni, Simona Tavolari & Giovanni Brandi. (2021) Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?. Frontiers in Oncology 11.
Crossref
Crossref
Alessandro Rizzo. (2021) Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.. Translational Oncology 14:12, pages 101246.
Crossref
Crossref
Alessandro Rizzo, Angela Dalia Ricci & Giovanni Brandi. (2021) Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy 13:8, pages 637-644.
Crossref
Crossref
Consolato M. Sergi. 2021. Liver Cancer. Liver Cancer
1
38
.
Alessandro Rizzo. (2021) The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer. Cancer Treatment and Research Communications 27, pages 100360.
Crossref
Crossref
Alessandro Rizzo & Giovanni Brandi. (2021) Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treatment and Research Communications 27, pages 100328.
Crossref
Crossref
Yin Zongyi & Li Xiaowu. (2020) Immunotherapy for hepatocellular carcinoma. Cancer Letters 470, pages 8-17.
Crossref
Crossref
Hye Won Lee, Kyung Joo Cho, Soon Young Shin, Ha Yan Kim, Eun Ju Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn & Kwang-Hyub Han. (2019) Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma. Journal of Liver Cancer 19:2, pages 108-116.
Crossref
Crossref
Brynjar Mauseth, Ketil André Camilio, Jihua Shi, Clara Louise Hammarström, Øystein Rekdal, Baldur Sveinbjørnsson & Pål-Dag Line. (2019) The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma. Molecular Therapy - Oncolytics 14, pages 139-148.
Crossref
Crossref
Elena De Mattia, Erika Cecchin, Michela Guardascione, Luisa Foltran, Tania Di Raimo, Francesco Angelini, Mario D’Andrea & Giuseppe Toffoli. (2019) Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World Journal of Gastroenterology 25:29, pages 3870-3896.
Crossref
Crossref
Chih-Ling Chung, Shih-Wei Wang, Wei-Chih Sun, Chih-Wen Shu, Yu-Chen Kao, Meng-Shin Shiao & Chun-Lin Chen. (2018) Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma. Biochemical Pharmacology 154, pages 39-53.
Crossref
Crossref
Wenjing Jiang, Guangxin Li, Weidong Li, Ping Wang, Peng Xiu, Xian Jiang, Bing Liu, Xueying Sun & Hongchi Jiang. (2018) Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na+/K+-ATPase activity and hypoxia-inducible pathways. Scientific Reports 8:1.
Crossref
Crossref
Jordan N. Markowitz & Karen M. Fancher. (2018) Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:3, pages 357-369.
Crossref
Crossref
A-Rum Yoon, JinWoo Hong, Minjung Kim & Chae-Ok Yun. (2018) Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions. Scientific Reports 8:1.
Crossref
Crossref
Galina Khemlina, Sadakatsu Ikeda & Razelle Kurzrock. (2017) The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Molecular Cancer 16:1.
Crossref
Crossref
Rinku Dutta & Ram I. Mahato. (2017) Recent advances in hepatocellular carcinoma therapy. Pharmacology & Therapeutics 173, pages 106-117.
Crossref
Crossref
David J. Pinato, Alessia Dalla Pria, Rohini Sharma & Mark Bower. (2017) Hepatocellular carcinoma. AIDS 31:5, pages 603-611.
Crossref
Crossref
Peng Han, Hali Li, Xian Jiang, Bo Zhai, Gang Tan, Dali Zhao, Haiquan Qiao, Bing Liu, Hongchi Jiang & Xueying Sun. (2017) Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells. Molecular Oncology 11:3, pages 320-334.
Crossref
Crossref
Jian Niu, Yue Wang, Ji Wang, Liu Bin & Xin Hu. (2016) Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer. Aging 8:12, pages 3520-3534.
Crossref
Crossref
Shuyao Tang, Gang Tan, Xian Jiang, Peng Han, Bo Zhai, Xuesong Dong, Haiquan Qiao, Hongchi Jiang & Xueying Sun. (2016) An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. Oncotarget 7:45, pages 73257-73269.
Crossref
Crossref
B. Bock, D. Hasdemir, F. Wandrer, T. Rodt, M. P. Manns, K. Schulze-Osthoff & H. Bantel. (2016) Serum cell death biomarker mirrors liver cancer regression after transarterial chemoembolisation. Alimentary Pharmacology & Therapeutics 44:7, pages 747-754.
Crossref
Crossref
Jella-Andrea Abraham & Olga Golubnitschaja. (2016) Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon?. Personalized Medicine 13:5, pages 455-467.
Crossref
Crossref
Joerg Trojan & Christoph Sarrazin. (2016) Complete Response of Hepatocellular Carcinoma in a Patient With End-stage Liver Disease treated With Nivolumab: Whishful thinking or Possible?. American Journal of Gastroenterology 111:8, pages 1208-1209.
Crossref
Crossref
Fabian Finkelmeier, Özge Canli, Andrea Tal, Thomas Pleli, Jörg Trojan, Michael Schmidt, Bernd Kronenberger, Stefan Zeuzem, Albrecht Piiper, Florian R. Greten & Oliver Waidmann. (2016) High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. European Journal of Cancer 59, pages 152-159.
Crossref
Crossref
Jörg Trojan, Stephan Zangos & Andreas A. Schnitzbauer. (2016) Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: Standards and Developments. Visceral Medicine 32:2, pages 116-120.
Crossref
Crossref